Receptor Targets
Weight Loss (Preclinical)
GI Side Effects
Lower Food Intake
Chimeric Peptide Innovation
GEP-44 is part of a series of chimeric peptides designed to target 2 key receptors, offering a fundamentally differentiated approach to metabolic care.
Dual Receptor Targeting
Neuropeptide Y-Receptor (Y2-R)
Reduces food intake (FI) through appetite suppression signalling pathways.
GLP1-R
Improves glucose regulation, insulin release, and metabolic control.
Preclinical Highlights
-
In preclinical studies (male and female rats), GEP-44 has shown a significant reduction in food intake (12–65%), improved glucose tolerance and protection of beta-islet cells against inflammatory damage while providing cardio and neuro protection.
-
Chimeric Peptide (GEP-44) reduces body weight, both energy intake and energy expenditure in diet-induced obese rats.
-
Findings suggest that GEP-44 and related peptides may offer a safe and effective treatment option for obesity and type 2 diabetes.
GEP-44 dual receptor mechanism — GLP1-R & Y2-R agonism at the cellular level
Single-Molecule Simplicity
GEP-44 is a monomeric peptide that acts as a triple agonist on GLP-1 and Peptide YY (PYY) receptors Y1 and Y2, combining the benefits of GLP-1 and NPY signalling pathways.
GLP-1R Activation
Y2-R Activation
Y1-R Activation
Superior Efficacy & Tolerability
Over existing GLP-1 drugs (Ozempic®, Wegovy®, Mounjaro® etc.)
GEP-44 vs. Liraglutide — Obese Rat Studies
Preclinical Data Summary
In obese rat studies, GEP-44 achieved ~15% weight loss vs. ~9% for liraglutide, with 39% lower food intake compared to 20% for liraglutide — demonstrating nearly double the efficacy across key metabolic measures.
Weight Loss
Food Intake Reduction
FI Reduction Range
Receptor Targets
No Gastrointestinal Side Effects
No nausea or vomiting observed (even in shrew models), a critical differentiator since GI events account for >40% of adverse effects in current GLP-1RA drugs.
The Problem with Current Drugs
GI events (nausea, vomiting, diarrhea) account for over 40% of reported adverse effects in existing GLP-1 receptor agonist drugs like Ozempic® and Wegovy®. This is the #1 reason patients discontinue treatment.
GEP-44's Advantage
Y1-R activation provides an anti-emetic effect, fundamentally eliminating the nausea and vomiting that plague every other GLP-1 therapeutic on the market or in clinical trials.
Short-Acting Benefit
GEP-44's rapid offset allows flexible dosing and significantly reduced risk of gastric paralysis or malaise — conditions commonly associated with long-acting GLP-1 agonists.
Flexible Dosing
Rapid onset and offset enables patient-centric dosing schedules.
Reduced Risk
Lower probability of gastroparesis and persistent side effects.
Better Compliance
Patients can adjust dosing without prolonged drug accumulation.
Controlled Response
Predictable pharmacokinetics with minimal overshoot.
Favourable Profile
Lacking the nausea, vomiting, and malaise commonly associated with other GLP-1 agonists. Click each card to learn more.
Superior Weight Loss & Glucose Control
Tap to learn more
Weight Loss & Glucose
Improved weight loss and glucose control through triple-agonist synergy. Preclinical data shows ~15% body weight reduction — nearly double that of liraglutide in matched models.
β-Cell Mass Preservation
Tap to learn more
Beta-Islet Protection
Protection of beta-islet cells against inflammatory damage, thereby protecting against the exacerbation of obesity and diabetic pathophysiology. Preservation of β-Cell Mass and protection of β-islet cells from inflammation.
Reduced GI Side Effects
Tap to learn more
Zero GI Events
Reduced gastrointestinal side effects and minimal malaise. No nausea or vomiting observed even in sensitive shrew models — a massive competitive advantage where >40% of adverse events in current drugs are GI-related.
Enhanced Tolerability
Tap to learn more
Better Than Ozempic®
Enhanced tolerability compared to existing GLP-1 agonists (e.g., Ozempic®). The Y1-R activation pathway provides a built-in anti-emetic mechanism that competitors simply cannot match.
Cardiovascular Support
Tap to learn more
Cardio Protection
Potential secondary benefits including cardiovascular support, cardio and neuro protection demonstrated in preclinical studies — extending GEP-44's therapeutic potential beyond metabolic disease.
Opioid Addiction Potential
Tap to learn more
Beyond Metabolic Care
Potential aid in reducing opioid addiction and withdrawal symptoms — opening entirely new therapeutic markets and indications for GEP-44 derived compounds.
How GEP-44 Compares
| Feature | Ozempic® | Wegovy® | Mounjaro® | GEP-44 |
|---|---|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 agonist | Dual (GIP + GLP-1) | Triple Agonist (GLP-1 + Y1 + Y2) |
| GI Side Effects | Common | Common | Common | None Observed |
| Weight Loss | ~9% | ~12–15% | ~15–22% | ~15% (preclinical) |
| Food Intake Reduction | ~20% | ~20% | ~25% | 39% |
| β-Cell Protection | Yes | |||
| Cardio & Neuro Protection | Some CV data | Some CV data | Under study | Demonstrated |
| Delivery Format | Injection | Injection | Injection | Non-Injectable Potential (Oral/Nasal) |
The Future of Metabolic Care
GEP-44 represents a fundamentally differentiated approach — triple-agonist design, zero GI side effects, and patent protection through 2042.